Catherine (Cath) McGowen is #hiring. Know anyone who might be interested?
Third Rock Ventures’ Post
More Relevant Posts
-
Great news for the Abata Therapeutics team, patients, and their families!
The FDA Fast Track designation for ABA-101 for the treatment of progressive multiple sclerosis will enable us to expedite our efforts to bring ABA-101 to patients. This designation advances our mission, as initiation of a first-in-human (FIH) Phase 1 study is imminent. #clinicaltrials #drugdevelopment #MS https://bit.ly/4dWJrOZ
To view or add a comment, sign in
-
Congrats to the MOMA Therapeutics team! One step closer to helping oncology patients.
Today marks a significant milestone for MOMA. We have dosed the first patient in the Phase 1 clinical trial for MOMA-313, a novel, highly potent and selective oral polymerase theta helicase inhibitor. MOMA-313 is being developed for subgroups of #prostatecancer, #pancreaticcancer and #breastcancer. To add to this exciting news, we are thrilled to share the selection of a development candidate for our second lead program, MOMA-341, an oral, potent and selective covalent Werner helicase inhibitor for the treatment of cancers with microsatellite instability. The MOMA team has worked hard to bring these two potential best-in-class molecules to the clinic through our proprietary KNOMATIC platform. Learn more about our MOMA-313, MOMA-341 and our KNOMATIC platform from MOMA CEO, Asit Parikh, M.D., Ph.D., below and read the release: https://lnkd.in/eVd3qR46
To view or add a comment, sign in
-
We are excited by Abata Therapeutics announcement today of a strategic investment from Bristol Myers Squibb supporting advancement of its Treg cell therapies into clinical development. One step closer to positively impacting patients and their families.
We are pleased to announce an equity investment from Bristol Myers Squibb to support the advancement of our Treg cell therapies into clinical development. This investment marks a significant milestone as we prepare to initiate trials for ABA-101 in progressive multiple sclerosis. Read more: https://bit.ly/3SRZMMB #biotech #investment #drugdiscovery
To view or add a comment, sign in
-
Welcome Chuck!
It is my pleasure to announce that I am joining the strong team at Terremoto Biosciences as its chief executive officer to transform patient care through science. I am honored to lead the efforts at Terremoto, inspired by the great team and vast potential of our work and united in our mission to develop highly targeted, small-molecule medicines with superior therapeutic benefits. Read more about my exciting next endeavor in the article below. For additional information, read our press release here: https://lnkd.in/gh6QF6Nc
To view or add a comment, sign in
-
This week we had the pleasure of hosting Biopharma Leaders of Color (BLOC) along with Sidley Austin LLP. It was inspiring to see many leading biopharma executives, investors, and innovators from across the country come together in an intimate setting to cultivate new relationships and strengthen existing bonds.
To view or add a comment, sign in
-
CARGO Therapeutics Phase 1 clinical study in patients with relapsed or refractory large B-cell lymphoma was published in The Lancet. Exciting news for the team!
Congratulations to Stanford University School of Medicine investigators on the first peer-reviewed publication of their Phase 1 clinical study evaluating our lead candidate CD22 CAR T-cell therapy, firi-cel, in the The Lancet! These impactful findings continue to demonstrate the curative potential of firi-cel and support the study design of our currently enrolling Phase 2 program. Learn more: https://lnkd.in/dH_QQNmK #CART #celltherapy
To view or add a comment, sign in
-
Congrats on the IND clearance of ABA-101! We look forward to watching your continued progress towards making a difference for patients living with Progressive Multiple Sclerosis.
We’re excited to announce IND clearance of ABA-101 for Progressive Multiple Sclerosis (MS). It’s the first open IND for our best-in-class autologous TCR-Treg cell therapy platform. We expect to initiate our Phase 1 study later this year. This is an important milestone for us and for patients. ABA-101 was specifically designed to benefit Progressive MS patients who have no or insufficient treatment options today. bit.ly/3LiotOa
To view or add a comment, sign in
-
Congratulations to Marea Therapeutics on their launch!
Introducing Marea – a clinical-stage biotech on a mission to leverage large-scale human genetics and adipose biology to revolutionize the treatment of #cardiometabolic diseases. Cardiovascular disease remains the number one killer in the U.S. and globally despite many advances over the past few decades. With a clinical-stage pipeline of first-in-class treatments and a team of some of the industry’s most dynamic scientists and company builders, we’re ready to take this challenge head on. Learn more about Marea in the release below or visit us at www.mareatx.com. https://lnkd.in/eM5MrHtD
To view or add a comment, sign in
-
Congratulations to the team!
We are so excited today to announce the pricing of our Initial Public Offering (IPO). We believe this important milestone will position us well as we look to further invest in our pipeline and advance our vision of transforming the lives of patients with CNS disorders. We expect shares of Rapport to start trading on Nasdaq Exchange tomorrow under the ticker symbol “RAPP”. Today would not have been possible without the relentless determination and commitment of our incredible team of Rapptors. Thank you! https://bit.ly/3yYDQZ0 #IPO #Innovation #BostonBiotech #Biotech
Rapport Therapeutics Announces Pricing of Initial Public Offering
globenewswire.com
To view or add a comment, sign in
44,125 followers